首页|冠状病毒膜融合抑制剂的研究进展

冠状病毒膜融合抑制剂的研究进展

扫码查看
冠状病毒(CoVs)是普遍一类感染人和动物的包膜RNA病毒,其特点是传播性强,致病性高,可引起人类和动物严重的临床症状及死亡.特异性药物的研发是控制冠状病毒感染的有效途径.膜融合过程是病毒进入靶细胞的关键步骤,也是当前特异性药物的热门靶点.目前动物类冠状病毒的膜融合特异性治疗药物仍处于研发阶段,而人源冠状病毒已有部分特异性药物用于临床.这类药物主要有肽类、小分子类和蛋白质类,同时一些提高药物抑制效力的方法正在积极开发中.该综述介绍了针对冠状病毒膜融合过程中各个靶点不同类型的抑制剂,并讨论了其优缺点及未来展望,以期为冠状病毒的治疗和控制提供参考.
Advances in Inhibitors of Membrane Fusion of Coronavirus
Coronaviruses are a type of enveloped RNA viruses that commonly infect humans and animals.They are known for their high transmissibility and pathogenicity,and can cause severe clinical symptoms and death.Developing specific medications is an effective strategy for controling coronavirus infection.The membrane fusion process plays a crucial role in the viral entry into target cells,and it is also a common target for specific medications.Drugs specifically targeting membrane fusion in animal coronaviruses are still in the research and development phase,while some drugs for human coronaviruses are already in clinical use.These medications pri-marily consist of peptides,small molecule and proteins,and some methods to improve the inhibitory effect of drugs are being actively developed.This review introduces various types of inhibitors that target different stages of the membrane fusion process in coronavirus,discussing their advantages,disadvantages and future potential to provide reference for the treatment and control of coronavirus.

coronavirusmembrane fusion inhibitorpeptidesmall moleculesprotein

伍歆蕊、郭钟蔚、黄勇、崔敏、夏静

展开 >

四川农业大学,动物医学院,成都 611130

四川农业大学,农业生物信息教育部重点实验室,成都 611130

冠状病毒 膜融合抑制剂 小分子 蛋白质

四川省自然科学基金青年项目四川省自然科学基金青年项目国家自然科学基金青年项目四川省区域创新合作项目国家现代农业产业技术体系四川鸡创新团队建设项目

24NSFSC767024NSFSC77643230290624QYCX0512SCCXTD-2024-24

2024

中国细胞生物学学报
中国科学院上海生命科学研究院,生物化学与细胞生物学研究所,中国细胞生物学学会

中国细胞生物学学报

CSTPCD
影响因子:0.554
ISSN:1674-7666
年,卷(期):2024.46(10)